Corporate Strategic M&A

A substantial portion of the transactions we handle are what many M&A participants would call “middle market” private transactions – even if the acquiror is a public company. These transactions vary substantially in size, industry, structure and complexity. These transactions all, however, share the fact that they are strategically important to the parties.

Corporate Strategic M&A transactions also often are handled partially by outside counsel and partially by the client’s existing staff (whether legal or other in-house experts). Our M&A lawyers understand how to partner effectively with our clients’ in-house staff to ensure we address the matters that need our attention, without duplicating efforts being undertaken in-house. We understand that the way a corporate buyer or seller approaches a potential transaction may differ significantly from the way a private equity sponsor approaches buying or selling a portfolio company in the typical private equity/leveraged buyout context.

Our Corporate Strategic M&A lawyers deliver comprehensive advice and practical results through a broad range of services for domestic and international clients. We regularly handle conventional and complex commercial transactions for public companies and privately held or family-owned enterprises. The services offered by our Corporate practice group are as diverse as our client base, enabling us to serve start-ups, entrepreneurs, middle-market companies, and some of the world’s most sophisticated industry leaders in mature and highly regulated industries.

Show More
Press Release
Haynes Boone Helps LadRx Secure Financing to Advance Cancer Therapeutics
June 23, 2023

A Haynes and Boone, LLP team led by Partners Rick Werner and Simin Sun represented LadRx Corporation in securing up to $11 million in non-dilutive financing from Xoma Corporation. LadRx, a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announced June 22 that it has transferred the royalty and milestone rights associated with arimoclomol and aldo [...]